Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Carlsmed (CARL) Liabilities and Shareholders Equity (2024 - 2026)

Carlsmed filings provide 2 years of Liabilities and Shareholders Equity readings, the most recent being $130.1 million for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 151.08% to $130.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $370.1 million, a N/A change, with the full-year FY2025 number at $130.1 million, up 151.08% from a year prior.
  • Liabilities and Shareholders Equity hit $130.1 million in Q4 2025 for Carlsmed, down from $134.9 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $134.9 million in Q3 2025 to a low of $51.8 million in Q4 2024.